This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Seelos Therapeutics, Inc.
Drug Names(s): DAB-452l, Aplindore, SLS006, SLS 006
Description: Aplindore (DAB-452) is a high affinity selective dopamine D2 receptor partial agonist. Aplindore has a half life of 6-8 hours.
Deal Structure: In November 2006, Neurogen acquired worldwide rights to Aplindore for an initial license fee payment of $3 million. Neurogen will also pay Wyeth milestone payments upon the successful achievement of clinical development and regulatory events, and royalties on worldwide sales.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
In August 2009, Ligand Pharmaceuticals and Neurogen announced they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock. The acquisition was completed in December 2009.
Ligand and Seelos
In September 2016, Ligand Pharmaceuticals announced the licensing of rights...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Ligand Pharmaceuticals, Inc.
Additional information available to subscribers only: